Nephrogen
Curative genetic medicines for kidney diseases
About Nephrogen
Nephrogen is a Stanford biotech spin-out developing curative genetic medicines for kidney and pancreatic diseases. Kidney disease alone affects 1 in 7 Americans, and neither indication has any approved gene-based therapies.
Nephrogen's underlying platform combines AI and high-throughput screening to engineer safer, more efficient, and less expensive gene delivery vehicles for reaching the kidney and pancreas, and has attracted non-dilutive funding from seven major pharmaceutical companies including Merck KGaA, Novartis, and Bristol Myers Squibb.
Company details
Funding
Total raised
$3.3M
Last stage
Seed
Investors
Founders
Demetri Maxim
Stanford computational biologist who conducted kidney disease research under Vivek Bhalla and Mark Kay. Also worked in Dr. George Church's lab at Harvard Medical School. Founded Nephrogen in 2022 based on his graduate research.
LinkedInVivek Bhalla
MD and Associate Professor of Medicine (Nephrology) at Stanford University. His laboratory focuses on molecular mechanisms of kidney disease including diabetes and hypertension. Supervised Demetri Maxim's graduate research.
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.